New scholarships worth EUR 417,000 awarded by Bayer Foundation to promote international talents

BayerWith approximately EUR 417,000, the Bayer Science & Education Foundation is providing a record amount for 65 talented young people who wish to realize international study and vocational training projects. The new scholarship recipients are students of the natural sciences, agriculture and medicine, as well those training to become science teachers or young people from skilled non-academic professions. "We need dedicated and creative young scientists if we are to successfully shape the future. That's why with the Bayer Fellowship Program we are helping talented young people to participate in special projects abroad," says Kemal Malik, Bayer Management Board member responsible for Innovation.

Today's "Bayer Fellowship program" follows the tradition of the first company scholarships initiated back in 1923 by Dr. Carl Duisberg, at that time Managing Director of the Bayer Group. Duisberg is regarded as a pioneer in the intensive cooperation between industry and universities, as well as in corporate social responsibility. Explains Dr. Carl-Heinz Duisberg, member of the Scientific Committee of the Bayer Fellowship Program and youngest grandchild of the program's founder: "My grandfather wanted to provide the best development opportunities for young talents because he saw this as a means of ensuring long-term benefits for society. He is also quoted as saying 'We must spend every spare penny on science - it is the best investment we can make.'"

All scholarships underline the mission of the Bayer foundation to work with young people and the next generation of scientists and opinion-leaders and to strengthen interest in the major challenges facing our society, such as health and agriculture.

Alongside the Otto Bayer, Jozef Schell and Carl Duisberg scholarships, the Bayer Fellowship Program also includes the Kurt Hansen and Hermann Strenger scholarships. For the third time, the Bayer Science & Education Foundation offers an additional special budget for "Talents for Africa". The scholarships are targeted at students and vocational trainees in natural science and medical disciplines who would like to realize a particular foreign study project and require financial support for this. In addition to Germany-based applicants who would like to study abroad, the foundation supports scholarship recipients from outside of Germany who wish to realize a comparable project in Germany.

Academic disciplines receiving support this year include the life sciences, chemistry, agriculture as well as human and veterinary medicine, with a total of 56 scholarships being awarded. Three Kurt Hansen scholarship recipients are also receiving assistance for teacher training in the natural sciences. The scholarships in the academic sector are being supplemented by Hermann Strenger scholarships to support young people looking to gain initial work experience abroad as part of a non-academic training program. This year, six young people from Germany are being supported who are planning a period abroad as part of their commercial, technical or health profession training.

Thanks to the Bayer scholarships, 47 new fellows from Germany will start their projects in 18 different countries: Argentina, Australia, Brazil, Chile, Ethiopia, France, Gabon, Israel, Mexico, Nicaragua, Russian Federation, Rwanda, Spain, Sri Lanka, Sweden, Switzerland, United Kingdom and the United States. Another 18 new scholarship winners will be able to implement their individual projects in Germany, coming from: Austria, Bangladesh, Brazil, Canada, Egypt, Finland, Italy, Mexico, Morocco, Netherlands, Nigeria, Pakistan, Russian Federation, Singapore, Syria, Tunisia, Turkey and United Kingdom.

The Bayer Science & Education Foundation thus is launching the eleventh round of its funding program, which offers targeted support for scientific exchange and international work experience for young people. It targets creative, highly motivated and socially committed young people with above-average grades.

The next round of applications starts in June 2018.

More information is available on the Internet at www.bayer-foundations.com.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...

Sports playbook helps doctors predict cancer patie…

In this season of global soccer competitions and hotly contested political primaries, bookies and pundits are scouring every evolving scrap of information and sifting thr...

FDA seeks public feedback on new drug approval tra…

Today the U.S. Food and Drug Administration issued a Federal Register notice, New Drugs Regulatory Program Modernization: Improving Approval Package Documentation, to ope...